Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases
May 04, 2021 16:05 ET | Source: Exagen Inc. Exagen Inc. Vista, California, UNITED STATES
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,
AHN Autoimmunity Institute jointly announced today the execution of a research collaboration agreement and an exclusive license agreement. The collaboration will focus on the development of novel patented biomarkers for diagnosis, prognosis and monitoring of autoimmune diseases, including systemic lupus erythematosus (SLE).
Exagen Inc Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Exagen Inc Announces Pricing of Public Offering of Common Stock
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.